Despite this, topical EGF products are available in other parts of the world and have demonstrated benefit, and the injectable Heberprot-P, which was developed and tested in Cuba, has been associated with decreased rates of diabetes-related amputation (51). Here, EGF is linked to diabetes mellitus.